AUS
NZ
UK
CA
USA
IND
Starpharma Holdings Limited (ASX:SPL), an Australian pharmaceutical firm specialising in dendrimer-based drug technologies, has unveiled a renounceable pro rata entitlement offer aiming to raise funds by issuing up to 56,123,791 new fully paid ordinary shares at $0.57 each. The offer, fully underwritten by Canaccord Genuity (Australia) Limited, is set on a 2-for-15 basis, enabling eligible shareholders to subscribe for two new shares for every fifteen held. Capital raised will support the advancement of Starpharma's DEP HER2-Lu Phase I clinical trial through its initial first-in-human and dose escalation phases, alongside further development of the company’s targeted dendrimer oncology assets. The offer’s timeline includes an ex-date of 17 July 2026 and an expected issue date of 11 August 2026.
Key Points
- Melbourne-based Starpharma Holdings Limited (ASX:SPL) focuses on dendrimer nanotechnology platforms for drug delivery and oncology applications.
- The company has launched a renounceable pro rata entitlement offer for up to 56,123,791 new fully paid ordinary shares at $0.57 per share on a 2-for-15 basis.
- Canaccord Genuity (Australia) Limited fully underwrites the offer, charging a 4.0% underwriting fee and a 2.0% management fee on proceeds; the offer closes on 4 August 2026 with an anticipated issue date of 11 August 2026.
- Investors should monitor results from the DEP HER2-Lu Phase I first-in-human and dose escalation stages as the primary near-term clinical milestone funded by this capital raise.
Starpharma’s Renounceable Entitlement Offer Details: 2-for-15 at $0.57 Per Share
Starpharma Holdings Limited has structured its entitlement offer on a renounceable basis, allowing eligible shareholders who opt not to participate to trade their rights on the ASX instead of letting them lapse. The offer ratio is two new shares for every fifteen existing shares held, priced at $0.57 per fully paid ordinary share. The maximum number of new shares to be issued, subject to rounding of fractional entitlements, is 56,123,791. Fractional entitlements will be rounded up to the nearest whole share, benefiting shareholders by avoiding fractional share losses.
Rights trading will commence on 17 July 2026 and conclude on 28 July 2026, providing shareholders a clear window to sell their rights if they choose not to subscribe. Offer documents are expected to be dispatched on 23 July 2026, detailing participation terms and conditions. The offer closes on 4 August 2026, with deferred settlement trading of new shares starting 29 July 2026. Normal T+2 trading is anticipated from 12 August 2026, and the first settlement date for both deferred and normal trades is 14 August 2026. The Appendix 3B filing did not disclose the total gross proceeds expected from the offer.
Canaccord Genuity Fully Underwrites Starpharma’s Entitlement Offer
The entitlement offer is fully underwritten by Canaccord Genuity (Australia) Limited, a prominent capital markets firm active in the Australian small and mid-cap sectors. This full underwriting provides Starpharma with certainty regarding the capital to be raised, as the underwriter is contractually obligated to subscribe for any shares not taken up by eligible shareholders, subject to the underwriting agreement’s terms. Canaccord Genuity will receive a 4.0% underwriting fee and a 2.0% management fee on the offer proceeds for its lead manager role.
Starpharma disclosed that Canaccord Genuity's underwriting commitment is subject to termination events detailed in the Summary of the Underwriting Agreement within the company’s Investor Presentation dated 15 July 2026. Additionally, a party referenced under ASX Listing Rule 10.11 is involved in underwriting or sub-underwriting the offer, fulfilling disclosure requirements regarding related parties or substantial holders. Brokers processing acceptances or renunciations for eligible shareholders will not receive separate handling fees or commissions. Standard share registry, external adviser, and ASX administrative fees will be incurred by Starpharma in connection with the offer.
DEP HER2-Lu Phase I Study: Main Clinical Milestone Funded by the Offer
Proceeds from the entitlement offer will primarily fund the completion of the first-in-human and dose escalation stages of the DEP HER2-Lu Phase I study. The DEP HER2-Lu program is a targeted dendrimer conjugate evaluated clinically, focusing on HER2, a well-established oncology target linked to aggressive cancers. The first-in-human study is a pivotal early clinical milestone assessing safety, tolerability, and pharmacokinetics before advancing to higher doses or broader patient groups.
The dose escalation phase involves incrementally increasing the investigational agent’s dose to identify the maximum tolerated dose and characterize drug behavior at varying exposure levels. Progress through these stages is essential before moving to later-stage efficacy trials. Investors tracking Starpharma’s clinical pipeline will view the DEP HER2-Lu Phase I study progress as a critical near-term value driver. Specific timelines or participant numbers for these stages were not disclosed in this update.
Advancing Dendrimer Oncology Assets: Secondary Use of Capital
Besides the DEP HER2-Lu Phase I program, funds will support the development and acceleration of additional targeted dendrimer-based oncology assets. Dendrimer technology is central to Starpharma’s business, with its proprietary DEP platform employing highly branched nanoscale polymers to enhance drug delivery. By conjugating active pharmaceutical ingredients to dendrimers, the platform aims to improve targeting, reduce systemic toxicity, and enhance therapeutic outcomes versus traditional formulations.
Allocating capital to multiple dendrimer oncology assets reflects Starpharma’s multi-asset strategy, diversifying its pipeline to mitigate risks associated with single programs. The company did not specify which additional oncology assets will receive investment or their current development stages in this update.
Oversubscription Facility Enables Eligible Shareholders to Apply for Up to 100% Additional Shares
The entitlement offer includes an oversubscription facility permitting eligible shareholders who fully subscribe to their entitlement to apply for additional shares at $0.57 each, capped at 100% of their initial entitlement. For example, a shareholder entitled to 10,000 new shares may apply for up to 10,000 extra shares through oversubscription. This provision allows shareholders confident in Starpharma’s prospects to increase their holdings if shares are available.
However, Starpharma and Canaccord Genuity retain discretion to scale back oversubscription applications. Any excess application funds will be refunded without interest after allotment, consistent with Australian market practices. Investors should note that additional allocations beyond base entitlements are not guaranteed.
Entitlement Offer Timeline: Key Dates from Ex-Date to Settlement
The company’s detailed timetable includes an ex-date of 17 July 2026, the record date of 20 July 2026 determining eligible shareholders, and expected dispatch of offer documents on 23 July 2026. Rights trading on the ASX runs from 17 July to 28 July 2026, allowing shareholders to sell rights if desired. The offer closes on 4 August 2026, with the last possible extension date being 30 July 2026.
Deferred settlement trading of new shares is expected to begin on 29 July 2026, with the issue date set for 11 August 2026. Normal T+2 trading starts on 12 August 2026, and the first settlement date for both deferred and normal trades is 14 August 2026. New shares issued will rank equally with existing fully paid ordinary shares from the issue date.
Starpharma’s DEP Platform and Oncology Focus Underpin This Capital Raise
Starpharma Holdings Limited is an Australian biopharmaceutical company focused on developing dendrimer-based products across pharmaceutical, agricultural, and other sectors. Its proprietary DEP drug delivery platform conjugates drugs to dendrimer structures to modify distribution, tolerability, and efficacy. Oncology is a core focus area, with the HER2-targeted program funded by this raise aligning with precision oncology strategies.
HER2 (human epidermal growth factor receptor 2) is a validated target in cancers such as breast and gastric cancer. Starpharma’s DEP HER2-Lu program applies dendrimer technology to develop a differentiated therapeutic candidate. The company’s broader effort to advance multiple dendrimer-based oncology assets indicates a strategy to build a diversified pipeline, managing development risk and creating opportunities for future licensing, partnerships, or commercialization. No specific partnership or commercial agreements were disclosed in this update.
Risk Factors Related to Starpharma’s Clinical-Stage Oncology Programs
As a clinical-stage pharmaceutical company, Starpharma faces risks investors must consider. The DEP HER2-Lu Phase I study’s early-stage clinical research involves inherent uncertainties, including safety, tolerability, and efficacy outcomes. There is no assurance the program will progress to later stages. Potential delays, regulatory hurdles, adverse events, or patient enrollment challenges could impact timelines and results.
Starpharma operates as a development-stage biopharmaceutical company, relying on capital raises like this entitlement offer to fund research and clinical activities rather than generating significant product revenue. Equity issuance carries dilution risks for shareholders who do not or cannot participate. The underwriting agreement with Canaccord Genuity is subject to termination events outlined in the 15 July 2026 Investor Presentation, which could affect capital raise certainty. Investors should thoroughly review all offer materials before investing.
